innerbuddies gut microbiome testing

Gut Microbiome & PCOS: How Insulin Resistance Is Influenced

If you have PCOS with insulin resistance, you’re not just managing hormones—you’re also managing a whole ecosystem inside your gut. Research increasingly suggests that the gut microbiome can influence how your body responds to insulin by shaping inflammation, gut barrier integrity, and how food-derived compounds are processed.

One key connection is that an imbalanced microbiome may promote “low-grade” inflammation and alter gut permeability. When the intestinal barrier is less robust, microbial components can more easily interact with the immune system, potentially worsening insulin signaling. At the same time, changes in microbial diversity and the types of bacteria present can affect the production of short-chain fatty acids (SCFAs)—important metabolites that help regulate blood sugar control, support gut health, and influence metabolic pathways linked to PCOS.

Gut bacteria also interact with hormone metabolism and energy balance. Through their effects on bile acids, fiber fermentation, and microbial metabolites that signal through metabolic receptors, the microbiome can influence appetite regulation, fat storage, and insulin sensitivity. The good news: targeted, science-backed lifestyle strategies—especially those that support beneficial microbes and increase SCFA production—may help improve metabolic outcomes alongside your broader PCOS care plan.

Test Your Gut Microbiome for PCOS & Insulin Resistance Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

PCOS with insulin resistance

Polycystic ovary syndrome (PCOS) frequently coexists with insulin resistance, amplifying glucose instability, weight management challenges, irregular periods, and androgen-related skin changes. Recent research highlights the gut microbiome as a modifiable pathway that may influence these features, with PCOS and impaired glucose regulation showing shifts in microbial composition and function—especially in carbohydrate fermentation, bile acid metabolism, and short-chain fatty acid (SCFA) production. A gut-focused perspective can complement standard endocrine and metabolic treatment by addressing inflammation, gut barrier integrity, and energy balance that underlie PCOS symptoms.

Key mechanisms involve SCFAs (butyrate, propionate, acetate) produced from fiber fermentation, which support gut barrier function and insulin sensitivity; bile acids transformed by gut microbes that signal through FXR and TGR5 to regulate glucose and energy balance; and the risk of metabolic endotoxemia from dysbiosis that worsens insulin signaling. Practical strategies emphasize increasing diverse, fermentable fiber (legumes, whole grains, vegetables) to boost SCFA output and improve glycemic control, with potential but variable benefits from targeted probiotics or postbiotics as part of a broader, personalized approach.

Testing the gut microbiome can provide personalized insight for PCOS with insulin resistance, revealing functional gaps in SCFA production and bile acid processing that help explain individual patterns of blood sugar swings, cravings, and weight-management difficulty. The InnerBuddies test is positioned as a tool to map microbiome function, guide targeted dietary and supplement decisions, and monitor shifts in gut function toward improved metabolic health, thereby complementing conventional PCOS care.

  • Low abundant butyrate producers Faecalibacterium prausnitzii, Roseburia spp., Eubacterium rectale, and Ruminococcus bromii reduce SCFA output (butyrate/propionate/acetate), weakening gut barrier and worsening insulin sensitivity in PCOS with IR.
  • Depletion of Akkermansia muciniphila (often alongside beneficial Bifidobacteria) impairs mucosal integrity, promoting metabolic endotoxemia and inflammation that can worsen insulin resistance and androgen-associated symptoms.
  • Expansion of pathobionts Escherichia/Shigella, Klebsiella, Ruminococcus gnavus, Parabacteroides distasonis, Streptococcus, and Eggerthella lenta drives systemic inflammation and endotoxemia, hindering insulin signaling.
  • Altered bile acid metabolism by gut microbes shifts FXR/TGR5 signaling, affecting glucose control, energy balance, and inflammatory pathways in PCOS.
  • Microbiome-derived signals influence gut hormones (GLP-1, PYY) and satiety, so favorable taxa support better post-meal glucose responses, while dysbiosis impairs this axis.
  • Dietary strategies that boost diverse, fermentable fiber (legumes, whole grains, vegetables) can selectively enrich SCFA producers and Akkermansia, improving microbiome function and insulin sensitivity in PCOS.
Test Your Gut Microbiome for PCOS & Insulin Resistance Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

PCOS

PCOS (polycystic ovary syndrome) frequently travels with insulin resistance, which can worsen androgen excess, ovulatory dysfunction, weight gain, and cardiometabolic risk. While PCOS is often treated from an endocrine and metabolic angle, emerging research highlights the gut microbiome as an additional modifiable pathway. In people with PCOS and insulin resistance, studies have reported differences in gut microbial composition and function—particularly shifts in bacteria involved in carbohydrate fermentation, bile acid metabolism, and short-chain fatty acid (SCFA) production that may influence how efficiently the body regulates glucose and fat storage.

Several mechanisms help explain the gut–insulin connection. SCFAs such as butyrate, propionate, and acetate—produced when gut microbes ferment dietary fiber—can support gut barrier integrity, reduce inflammatory signaling, and modulate metabolic pathways relevant to insulin sensitivity. Microbial metabolites also shape bile acids, which act as signaling molecules through receptors like FXR and TGR5 to affect glucose metabolism and energy balance. Meanwhile, dysbiosis may promote low-grade inflammation and “metabolic endotoxemia” (elevated inflammatory signals linked to impaired gut barrier function), further impairing insulin signaling.

Current evidence suggests that restoring microbiome function—not just altering individual nutrients—may help improve insulin resistance in PCOS. Practical, science-backed strategies often focus on increasing diverse, fermentable fiber intake (e.g., legumes, whole grains, vegetables, and prebiotic-rich foods), which supports beneficial SCFA-producing pathways, and choosing dietary patterns shown to improve glycemic control. Some people may also benefit from targeted probiotic or postbiotic approaches, though responses can vary by strain, baseline microbiome, and diet quality. Overall, a gut-supportive approach may complement standard PCOS care by addressing inflammation, bile acid signaling, and microbial metabolite outputs that influence insulin regulation.

  • Difficulty maintaining stable blood sugar (blood sugar spikes/crashes)
  • Increased cravings and difficulty controlling appetite
  • Weight gain or difficulty losing weight, especially around the abdomen
  • Irregular periods or worsening menstrual cycle regularity
  • Acne or other skin flare-ups (often linked to androgen excess)
  • Hair thinning or increased facial/body hair growth
Test Your Gut Microbiome for PCOS & Insulin Resistance Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

PCOS with insulin resistance

This is relevant for people with PCOS who are also experiencing insulin resistance—especially if you notice trouble keeping blood sugar steady (spikes and crashes), strong cravings, or difficulty feeling satisfied after meals. If these metabolic patterns are contributing to weight gain (often more noticeable around the abdomen) and overall difficulty losing weight despite standard efforts, a gut-microbiome–focused approach may be a helpful complementary angle.

It’s also relevant if your PCOS symptoms appear tightly linked to metabolic stress or inflammation, such as worsening menstrual irregularity, acne/skin flare-ups, or changes in hair growth (including thinning hair or increased facial/body hair). Because gut dysbiosis may promote low-grade inflammation and “metabolic endotoxemia,” improving microbiome function may support the hormonal and metabolic signals that influence androgen excess and ovulation.

Finally, this is relevant for those who want science-backed, practical strategies beyond “one nutrient at a time.” If you’re interested in approaches that emphasize diverse fermentable fibers (prebiotic-rich foods like legumes, whole grains, and vegetables) to promote beneficial short-chain fatty acids and healthier bile acid signaling, this can fit well alongside standard PCOS care. Some individuals may also consider strain-specific probiotics or postbiotics as optional add-ons, particularly when diet quality is improved and symptoms suggest gut-related contributions to insulin sensitivity.

PCOS is one of the most common endocrine disorders in people of reproductive age, affecting roughly 8–13% worldwide. Because PCOS is frequently linked with insulin resistance and metabolic dysfunction, a substantial portion of individuals with PCOS also experience impaired glucose regulation—estimates vary by population and diagnostic criteria, but insulin resistance is commonly reported in about 50–70% of people with PCOS.

In people with PCOS and insulin resistance, the metabolic symptoms described in your overview—such as unstable blood sugar, appetite dysregulation/cravings, and difficulty losing weight (often with increased abdominal fat)—are also commonly observed in clinical practice. Irregular menstrual patterns (ranging from infrequent cycles to difficulty maintaining regularity) and androgen-related skin changes (acne flares) are prevalent features of PCOS, reflecting the condition’s hormonal and insulin-linked biology.

Gut microbiome differences are increasingly recognized as part of the PCOS–insulin resistance picture, but the condition itself still has clear epidemiologic anchors: PCOS is widespread (about 1 in 10 reproductive-age people), and insulin resistance is common among those affected. This means that a large number of individuals with PCOS may plausibly experience microbiome-associated shifts in carbohydrate fermentation, bile acid signaling, and short-chain fatty acid (SCFA)–related pathways that can influence inflammation and insulin sensitivity—aligning with the symptom cluster you listed (blood sugar instability, weight gain, cycle irregularity, and androgen-driven skin/hair changes).

Test Your Gut Microbiome for PCOS & Insulin Resistance Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Gut Microbiome & PCOS: How Insulin Resistance Is Influenced

PCOS with insulin resistance is increasingly understood as a condition that may be influenced by the gut microbiome. Compared with people without PCOS, individuals with PCOS and impaired glucose regulation often show shifts in microbial composition and metabolic activity, particularly in pathways tied to carbohydrate fermentation and the production of short-chain fatty acids (SCFAs). These microbiome changes can affect how efficiently the body manages glucose and fat storage, potentially contributing to insulin resistance, weight gain, and the appetite and blood-sugar instability many people experience.

SCFAs such as butyrate, propionate, and acetate—made when gut microbes ferment dietary fiber—play a key role in metabolic health. They help support the gut barrier, reduce low-grade inflammatory signaling, and can influence metabolic pathways involved in insulin sensitivity. When dysbiosis leads to a less robust gut barrier, inflammatory molecules may cross more easily into circulation (“metabolic endotoxemia”), further worsening insulin signaling. This inflammatory cascade can align with common symptoms like blood sugar swings, cravings, and difficulty losing weight, as well as skin and cycle issues that often track with metabolic stress.

Gut microbes also interact with bile acid metabolism, producing metabolites that shape signaling through receptors like FXR and TGR5—pathways that affect glucose control, energy balance, and inflammation. In PCOS with insulin resistance, altered bile acid processing may disrupt these signaling networks, amplifying androgen-related effects and cardiometabolic risk. While standard care remains essential, restoring microbiome function—especially by increasing diverse, prebiotic-rich fiber intake (legumes, whole grains, vegetables)—may help improve SCFA output and bile acid signaling, which can support more stable blood sugar, reduced inflammation, and potentially better symptom control.

Test Your Gut Microbiome for PCOS & Insulin Resistance Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Gut Microbiome and PCOS with insulin resistance

  • Reduced fiber-fermentation leading to lower SCFA production (butyrate/propionate/acetate), which can impair insulin sensitivity and metabolic signaling
  • Gut barrier dysfunction and increased gut permeability (“metabolic endotoxemia”), allowing LPS and other inflammatory signals to enter circulation and worsen insulin signaling
  • Altered gut microbial carbohydrate metabolism and energy harvest, promoting glucose dysregulation and increased fat storage that can intensify insulin resistance
  • Inflammatory tone modulation via SCFAs (especially butyrate), where dysbiosis can shift immune signaling and drive low-grade systemic inflammation associated with PCOS insulin resistance
  • Changes in bile acid composition and microbial bile acid transformations that disrupt FXR/TGR5 signaling, affecting glucose control, lipid metabolism, and inflammation
  • Microbiome-driven regulation of appetite and glycemic stability through gut peptides and metabolite signaling (including SCFA effects on GLP-1/PYY pathways), contributing to cravings and blood-sugar swings

In PCOS with insulin resistance, the gut microbiome often shows shifts in both which microbes are present and what they do metabolically—especially regarding carbohydrate fermentation. When intake of fermentable fiber is low or the microbial community is less diverse, the gut may produce fewer short-chain fatty acids (SCFAs) such as butyrate, propionate, and acetate. Because these metabolites help support insulin sensitivity and metabolic signaling, reduced SCFA output can contribute to poorer glucose handling, increased fat storage tendencies, and the blood-sugar instability that commonly worsens PCOS symptoms.

SCFAs also help maintain gut barrier integrity, so dysbiosis can indirectly worsen insulin resistance through inflammation. If the intestinal lining becomes more permeable (“leaky gut”), microbial components like LPS can cross into circulation more easily, contributing to low-grade systemic inflammation—often described as “metabolic endotoxemia.” This inflammatory tone can interfere with insulin signaling pathways and amplify downstream effects on appetite, cravings, and metabolic stress, linking microbiome changes to both glycemic swings and difficulty losing weight.

Beyond SCFAs, gut microbes influence insulin resistance through their effects on bile acids and gut–brain/hormone signaling. Certain microbes transform bile acids into signaling-active metabolites that engage receptors such as FXR and TGR5; altered bile acid processing can disrupt glucose control, lipid metabolism, and inflammatory pathways relevant to PCOS. In parallel, microbial metabolites and SCFA-driven signaling can affect gut hormones (including GLP-1 and PYY), which regulate satiety and post-meal glucose responses. Together, these microbiome-driven changes can reinforce insulin resistance by affecting appetite regulation, energy harvest, and the inflammatory and metabolic signaling networks that underlie PCOS.

Test Your Gut Microbiome for PCOS & Insulin Resistance Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Microbial patterns summary

In PCOS accompanied by insulin resistance, studies commonly report a gut microbiome that differs from metabolically healthy controls in both composition and metabolic “function,” particularly in how efficiently microbes ferment available carbohydrates. People with impaired glucose regulation often show reduced microbial diversity and shifts in taxa linked to carbohydrate breakdown, which can translate into lower production of short-chain fatty acids (SCFAs) when fermentable fiber intake is inadequate. Because SCFAs such as butyrate, propionate, and acetate help support insulin sensitivity and strengthen gut barrier integrity, these functional changes can align with the metabolic instability, weight-management challenges, and inflammation that frequently accompany insulin resistance.

A second recurring pattern involves a gut barrier–inflammation axis: when the microbiome is less supportive of mucosal integrity, the intestine may become more permeable, allowing bacterial components (e.g., LPS) to more easily reach circulation and promote low-grade systemic inflammation. This “metabolic endotoxemia” profile can interfere with insulin signaling and amplify downstream hormonal and inflammatory pathways that worsen metabolic symptoms. In this context, SCFAs are often central—not only for signaling through metabolic pathways, but also for reducing inflammatory tone by reinforcing the gut lining and modulating immune responses.

Finally, microbiome effects on bile acids and gut hormone signaling are frequently highlighted. Gut microbes can transform bile acids into metabolites that activate receptors such as FXR and TGR5, which regulate glucose homeostasis, energy balance, and inflammatory signaling; altered bile acid processing may therefore contribute to poorer insulin control and higher cardiometabolic risk. In parallel, microbial metabolites can influence secretion of gut-brain and metabolic hormones involved in satiety and post-meal glucose responses (including pathways associated with GLP-1 and PYY). Together, these patterns—impaired SCFA output, barrier dysfunction with inflammatory signaling, and disrupted bile acid/gut-hormone signaling—help explain how dysbiosis may reinforce insulin resistance-related features in PCOS.


Low beneficial taxa

  • Faecalibacterium prausnitzii
  • Roseburia spp.
  • Eubacterium rectale
  • Ruminococcus bromii
  • Akkermansia muciniphila
  • Bifidobacterium longum
  • Bifidobacterium adolescentis
  • Coprococcus comes


Elevated / overrepresented taxa

  • Escherichia/Shigella
  • Klebsiella
  • Bacteroides (e.g., Bacteroides fragilis group)
  • Ruminococcus gnavus
  • Parabacteroides distasonis
  • Streptococcus
  • Eggerthella lenta


Functional pathways involved

  • Carbohydrate fermentation to short-chain fatty acids (SCFAs) (butyrate/propionate/acetate production)
  • Butyrate-driven colonic epithelial barrier integrity and tight-junction signaling
  • Lipopolysaccharide (LPS) generation and metabolic endotoxemia–linked inflammation signaling
  • Bile acid transformation and bile acid receptor signaling (FXR/TGR5-mediated glucose and lipid regulation)
  • Microbial modulation of incretin and satiety hormone pathways (GLP-1 and PYY signaling) via metabolite signaling
  • Branched-chain amino acid (BCAA) and microbial amino-acid fermentation/derivative metabolism affecting insulin signaling
  • Modulation of mucin and glycans utilization (Akkermansia-linked mucosal turnover and gut barrier effects)


Diversity note

In PCOS accompanied by insulin resistance, gut microbiome studies often report lower microbial diversity compared with metabolically healthy controls. This reduction in diversity typically goes along with a shift in the overall balance of carbohydrate-fermenting communities—meaning the ecosystem may be less efficient at breaking down available fiber into beneficial microbial metabolites. When fermentable substrates are limited or the community is less resilient, the downstream metabolic “function” can tilt away from pathways that normally support metabolic stability.

A common diversity-related pattern also involves functional changes that accompany dysbiosis. Even when specific taxa vary between individuals, many studies describe impaired capacity to generate short-chain fatty acids (SCFAs) such as butyrate, propionate, and acetate—key products of fiber fermentation. Lower SCFA output can weaken gut barrier integrity and reduce the anti-inflammatory signaling that helps keep systemic inflammation in check, which is especially relevant for insulin resistance. In turn, a less supportive microbial ecosystem can contribute to a cycle where inflammation and metabolic stress further undermine microbial balance.

Finally, altered diversity can coincide with changes in bile acid processing and gut hormone–related metabolic signaling. Because different microbial communities influence how bile acids are transformed and which metabolites reach receptors involved in glucose control and energy balance, a less diverse microbiome may disrupt these regulatory pathways. These microbiome-driven signaling changes can potentially reinforce insulin resistance features seen in PCOS, including greater post-meal glucose volatility and heightened inflammatory tone.


Test Your Gut Microbiome for PCOS & Insulin Resistance Get Your Gut Microbiome Test Subscription

Why generic solutions fail

  • Issue with generic solutions

    Generic solutions often fail for PCOS with insulin resistance because they treat “metabolism” as if it’s one uniform problem, rather than a gut-microbiome–linked network. Many broad-brush approaches focus on calorie restriction or general “healthy eating” without restoring the specific microbial functions that support insulin sensitivity—especially fiber fermentation pathways that generate SCFAs (butyrate, propionate, and acetate). If someone’s diet doesn’t provide consistently fermentable substrates (or if their gut environment is already dysbiotic), microbiome activity can remain shifted toward poorer SCFA output, leaving gut barrier integrity and glucose signaling less supported.

    Another reason generic solutions underperform is that they rarely address the barrier–inflammation axis that often accompanies dysbiosis in insulin resistance. When the gut lining is less robust, bacterial components such as LPS can more easily enter circulation and maintain low-grade systemic inflammation (“metabolic endotoxemia”). Standard plans that don’t target the drivers of mucosal resilience—such as the right kinds of prebiotic fibers, gradual microbiome-supportive dietary transitions, and strategies to reduce inflammatory triggers—may improve symptoms temporarily but don’t meaningfully lower the inflammatory tone that continues to impair insulin signaling.

    Finally, generic interventions may ignore microbiome-driven bile acid and gut-hormone signaling, which can be particularly relevant in PCOS. Gut microbes help convert and reshape bile acids into metabolites that activate receptors like FXR and TGR5, influencing glucose control, energy balance, and inflammation. They also contribute to the post-meal gut-hormone milieu (e.g., pathways involving GLP-1 and PYY) that affects appetite and blood-sugar stability. When an approach doesn’t account for individual variation in microbial bile-acid metabolism and SCFA production, it may fail to produce durable improvements in insulin resistance, cravings, or cycle/skin symptoms.

  • Common mistakes

    • Treating PCOS/insulin resistance as a single “metabolism” issue and not targeting microbiome-linked functions (especially carbohydrate fermentation and SCFA production).
    • Relying on generic calorie restriction or “eat healthy” guidance without ensuring consistent intake of fermentable fibers that support butyrate/propionate/acetate output.
    • Increasing fiber too quickly or choosing fiber types that don’t match the person’s current gut fermentation capacity, leading to poor tolerance and minimal microbiome functional change.
    • Ignoring the gut barrier–inflammation axis (e.g., ongoing endotoxin/LPS-driven low-grade inflammation) instead of using diet strategies that reinforce mucosal integrity and reduce inflammatory triggers.
    • Not addressing dysbiosis-related drivers of endotoxemia (e.g., inadequate fiber, highly processed foods, excess emulsifiers/alcohol, or persistent dietary patterns that worsen permeability) and expecting symptoms to improve anyway.
    • Overlooking microbiome-driven bile acid metabolism and related signaling (FXR/TGR5), which can be important for durable glucose and energy-balance improvements in some patients.
    • Skipping considerations for gut-hormone signaling impacts (GLP-1, PYY) and meal/glycemic patterns that influence post-meal glucose stability and satiety—assuming diet changes alone will fully correct insulin resistance.
    • Using one-size-fits-all probiotic/prebiotic regimens without accounting for individual baseline microbiome composition, functional deficits, and whether the intervention will meaningfully restore SCFA/bile-acid pathways.

What to do

  • General support strategies

    For PCOS with insulin resistance, supportive strategies often focus on improving gut microbiome function in ways that enhance metabolic health. Research suggests that people with PCOS and impaired glucose regulation may have altered microbial communities and changes in how efficiently their gut microbes ferment carbohydrates and produce metabolites linked to insulin sensitivity. Increasing gut microbial diversity and metabolic activity—primarily through consistent intake of fiber-rich, minimally processed foods—can help support more favorable fermentation patterns and metabolic signaling over time.

    A key target is boosting short-chain fatty acid (SCFA) production, especially butyrate, propionate, and acetate, which are generated when microbes ferment dietary fiber. These SCFAs help maintain the intestinal barrier, support anti-inflammatory signaling, and influence pathways involved in glucose regulation. When gut barrier integrity is weaker, inflammatory molecules may be more likely to cross into circulation (“metabolic endotoxemia”), which can worsen insulin signaling and contribute to symptoms like blood-sugar instability, cravings, and difficulty managing weight. Diet patterns rich in legumes, whole grains, vegetables, and other prebiotic fibers can help nourish SCFA-producing microbes and reduce inflammatory drive.

    Gut support also includes optimizing bile acid metabolism, since gut microbes convert and transform bile acids into metabolites that signal through receptors such as FXR and TGR5. These pathways affect glucose control, energy balance, and inflammation—processes closely tied to cardiometabolic risk in PCOS. In practice, emphasizing diverse plant-based foods and fiber fermentation substrates can support healthier bile acid signaling, while individualized adjustments (as guided by tolerance, GI symptoms, and overall diet quality) can further help stabilize metabolic responses. Standard medical care remains essential, but gut-focused nutrition strategies may complement it by improving the microbiome-derived signals that support insulin sensitivity.

  • Lifestyle recommendations

    • Increase dietary fiber (aim for a variety of non-starchy vegetables, legumes, whole grains, nuts/seeds) to support beneficial SCFA-producing gut bacteria.
    • Prioritize prebiotic foods regularly (e.g., beans/lentils, oats, chia/flax, garlic/onions, asparagus) rather than relying only on probiotics.
    • Adopt an insulin-sensitizing eating pattern: emphasize protein and high-fiber carbs, limit added sugars/refined starches, and spread carbs across meals to reduce blood-sugar swings.
    • Engage in regular exercise (a mix of aerobic activity and resistance training) as it can improve insulin sensitivity and may positively influence gut microbiome diversity.
    • Support gut barrier and reduce inflammatory triggers by minimizing ultra-processed foods and alcohol, and choosing healthy fats (olive oil, avocados, fatty fish).
    • If constipation or low stool frequency is present, address it with higher fiber gradually, adequate hydration, and consider discussing a clinician-guided plan to avoid GI flare-ups.

  • Nutrition recommendations

    • Prioritize diverse, prebiotic-rich fiber daily (e.g., legumes like lentils/beans, oats, barley, onions/garlic/leeks, asparagus, chia/flax) to support SCFA production and insulin sensitivity.
    • Choose low–glycemic-load carbohydrate sources and pair carbs with protein and healthy fats (e.g., Greek yogurt with berries/chia, quinoa with vegetables and olive oil, beans with vegetables) to reduce blood-sugar swings.
    • Increase omega-3 intake from food sources (e.g., salmon/sardines, mackerel) or consider an appropriate supplement if needed, to help dampen low-grade inflammation linked with insulin resistance.
    • Add probiotic foods consistently (e.g., yogurt with live cultures, kefir, sauerkraut, kimchi) while keeping fiber high, to support a more resilient microbiome composition.
    • Emphasize minimally processed, plant-forward meals (vegetables, nuts, seeds, olive oil) and limit added sugars and refined starches (sweets, sweetened drinks, white bread/pastries) to reduce dysbiosis and metabolic stress.
    • Support gut barrier health with adequate protein and micronutrients (e.g., eggs, poultry/fish, tofu/tempeh, and a variety of colorful vegetables) and avoid crash dieting, which can worsen metabolic regulation and tolerance of fiber.

  • Supplement considerations

    For PCOS with insulin resistance, supplement strategies often focus on supporting the gut ecosystem that drives carbohydrate fermentation and SCFA production (like butyrate, propionate, and acetate). When dietary fiber intake is insufficient or the microbiome is less diverse, SCFA output may be lower, which can weaken gut barrier integrity and contribute to higher inflammatory signaling—an issue that can worsen insulin sensitivity and amplify blood-sugar instability. Common supplement considerations therefore include prebiotic fibers (e.g., inulin-type fructans, partially hydrolyzed fiber, resistant starch) and, in some cases, targeted probiotics that may help promote a more favorable microbial balance and improve metabolic activity related to fermentation.

    Because gut microbes also interact with bile acid metabolism, supplements that influence microbial bile-acid transformations may be relevant. Changes in bile acid signaling can affect metabolic regulators (such as FXR and TGR5 pathways) that influence glucose handling, energy balance, and inflammation—processes closely linked to insulin resistance and cardiometabolic risk in PCOS. In practice, supplement approaches that increase fermentable substrate and may modulate bile acid–producing microbial functions are often considered alongside bile-supporting nutrients, while staying mindful that individual tolerance (especially GI comfort) and baseline diet patterns can determine what works best.

    Finally, many people with PCOS and insulin resistance are also managing low-grade inflammation and appetite or craving patterns that track with glycemic swings. For this reason, some supplement plans prioritize gut-barrier and anti-inflammatory support indirectly through microbiome-friendly interventions, rather than relying on single agents alone. Where probiotics are used, selecting strains with evidence for metabolic endpoints and considering duration and consistency matter; where prebiotics are used, starting low and gradually increasing can help avoid bloating or discomfort. Standard care for insulin resistance remains essential, and supplement choices work best when paired with a fiber-rich, minimally processed dietary pattern to maximize microbial SCFA output.

  • Retesting / monitoring note

    For PCOS with insulin resistance, microbiome-focused retesting is most informative when it’s tied to measurable metabolic changes rather than done repeatedly without context. In many cases, retesting is reasonable after a structured lifestyle or nutrition intervention—such as increasing dietary fiber to support SCFA-producing fermentation, improving prebiotic intake (legumes, whole grains, vegetables), and reducing factors that may worsen dysbiosis—has been followed consistently for long enough to allow the gut ecosystem and downstream metabolic signaling to stabilize. A common timeframe to consider is roughly 8–12 weeks, since that window often captures meaningful shifts in fermentation patterns and gut barrier-related inflammation.

    When retesting, prioritize panels that reflect the gut–metabolic axis that’s relevant to insulin resistance. This may include markers related to SCFA production or fermentation capacity (often inferred through stool metabolite profiles), indicators of gut barrier stress and low-grade inflammation (e.g., inflammatory markers and endotoxin-associated measures where appropriate), and any labs that show glucose regulation changes (fasting glucose, fasting insulin, HbA1c, or insulin resistance indices). If bile acid metabolism is a particular concern in your clinical picture, retesting may also include bile acid–related biomarkers that can help clarify whether changes in microbial bile acid conversion are occurring, since bile acid signaling through FXR/TGR5 can influence insulin sensitivity and energy balance.

    Because PCOS and insulin resistance can be influenced by medications, cycle stage, diet consistency, sleep, stress, and activity level, retesting works best when conditions are standardized as much as possible. If symptoms improve or metabolic markers normalize, retesting can help confirm whether the microbiome-related targets—such as improved SCFA output, reduced inflammatory signaling, and more favorable bile acid metabolite patterns—are aligning with those outcomes. Conversely, if results don’t shift as expected, the retesting period can be used to refine the plan (for example, adjusting fiber type and dosage for better tolerance and fermentation, addressing under-consumption of prebiotic foods, or re-evaluating contributors to dysbiosis) while ensuring standard PCOS/insulin-resistance care remains the foundation.

The importance of gut microbiome testing

  • Why testing matters

    Gut microbiome testing matters in PCOS with insulin resistance because the pattern of gut bacteria and their metabolic output can vary widely from person to person—even among individuals with similar lab results. Many people with impaired glucose regulation show differences in microbial composition and function, especially in pathways linked to fermenting carbohydrates and producing short-chain fatty acids (SCFAs) like butyrate, propionate, and acetate. Since SCFAs influence insulin sensitivity, gut barrier integrity, and inflammatory signaling, knowing how your microbiome is currently performing can help explain why blood sugar swings, cravings, and weight changes may be more pronounced for you than for others.

    Testing can also shed light on mechanisms beyond “more or less fiber,” including whether your gut ecosystem is supporting a stable gut lining and healthy immune activity. If microbial imbalance contributes to a weaker gut barrier, it may increase exposure to inflammatory molecules that can worsen insulin signaling (often described as metabolic endotoxemia). Microbiome profiles may help identify functional gaps—such as reduced SCFA-producing potential or signatures associated with bile acid dysregulation—that can further affect glucose control and energy balance.

    Finally, microbiome testing can support more personalized nutrition and supplement choices. Because gut microbes interact with bile acids and signaling pathways (including receptors like FXR and TGR5), two people can respond differently to the same dietary approach. By clarifying your starting point—what microbes and functions are dominant or missing—testing can guide targeted increases in prebiotic-rich foods (like legumes, whole grains, and vegetables) and help track whether interventions are actually shifting microbial function in a direction associated with improved metabolic health.

  • How InnerBuddies helps

    The InnerBuddies test can help people with PCOS and insulin resistance by showing how their gut microbiome is currently functioning, not just what foods they eat. Because microbiome patterns and metabolic outputs vary widely—even when bloodwork looks similar—InnerBuddies can highlight whether your gut ecosystem is supporting key functions tied to carbohydrate fermentation and short-chain fatty acid (SCFA) production (such as butyrate, propionate, and acetate). These SCFAs are important for metabolic health because they support gut barrier integrity, help temper low-grade inflammation, and can influence insulin sensitivity.

    InnerBuddies can also provide insight into potential mechanisms that may worsen insulin signaling, including signs of dysbiosis that could contribute to weaker barrier function and “metabolic endotoxemia.” When the gut lining is less robust, inflammatory molecules may be more likely to enter circulation and amplify insulin resistance and related symptoms like blood-sugar swings, cravings, and difficulty with weight management. By identifying functional gaps in the microbiome, the test can help you move beyond generic advice and toward understanding what might be driving your individual response.

    Finally, InnerBuddies can support more personalized nutrition by mapping microbiome-related factors that interact with bile acid metabolism and metabolic signaling pathways (including receptors such as FXR and TGR5). Since altered bile acid handling can affect glucose control, energy balance, and inflammation—processes that often intertwine with androgen-related risk—having a clearer starting point can guide targeted increases in prebiotic-rich fiber (like legumes, whole grains, and vegetables) and inform supplement choices. This makes it easier to choose interventions that fit your microbiome profile and track whether they’re shifting gut function in a more metabolically supportive direction.

Medical Evidence

  • Scientific evidence level

    2 [weak/emerging but inconsistent]

  • Clinical relevance note

    Where this stands clinically: At present, gut microbiome findings in PCOS with insulin resistance should be considered hypothesis-generating rather than practice-changing. While plausible mechanisms and some observational associations exist, reproducibility across studies is limited and confounding (diet, BMI, metformin/other medications, physical activity, antibiotics, and sequencing/processing differences) is a major threat. Reverse causality is also plausible: insulin resistance and metabolic dysregulation can themselves alter the gut environment, changing the microbiome.

    What would be needed for clinical translation: To reach clinically actionable status, future research would need (i) large, well-controlled prospective cohorts showing baseline microbiome features predict incident/worsening IR in PCOS (and ideally in subgroups defined by IR severity), (ii) microbiome-targeted randomized controlled trials with sufficient power, standardized interventions (e.g., specific strains/prebiotics with clear metabolic endpoints), and careful control of diet/medications, and (iii) mechanistic validation linking specific microbial functions/metabolites to insulin sensitivity with evidence beyond taxa abundance. Until such data are available, routine microbiome testing for PCOS+IR is not supported, and microbiome-targeted interventions should not be framed as established treatments for insulin resistance in PCOS.

Title Journal Year Link
The gut microbiome in polycystic ovary syndrome: a systematic review and meta-analysis Frontiers in Endocrinology 2021 View →
Gut microbiota and polycystic ovary syndrome: a review of mechanisms and clinical evidence Trends in Endocrinology & Metabolism 2020 View →
Altered gut microbiota composition and function in women with polycystic ovary syndrome Gut Microbes 2019 View →
Probiotics improve insulin resistance and hyperandrogenism in women with polycystic ovary syndrome: a randomized controlled trial European Journal of Endocrinology 2018 View →
Gut microbiota and insulin resistance in women with polycystic ovary syndrome Diabetologia 2012 View →

Frequently Asked Questions

    ¿Cuál es el papel del microbioma intestinal en el SOP de PCOS con resistencia a la insulina?
    Las diferencias en el microbioma pueden influir en la inflamación, la producción de SCFA, la señalización de ácidos biliares y la sensibilidad a la insulina. Es una vía potencialmente modificable, pero los resultados varían. Esta es información general y no sustituye a consejo médico.
    ¿Qué son los SCFA y por qué importan para la sensibilidad a la insulina?
    SCFA (butirato, propionato, acetato) se producen cuando las bacterias fermentan la fibra. Apoyan la barrera intestinal, reducen la inflamación de bajo grado y influyen en la señalización de la insulina.
    ¿Cómo puede la dieta cambiar el microbioma para ayudar con la IR en PCOS?
    Una dieta diversa y rica en fibra, especialmente fibras prebióticas fermentables, puede apoyar la producción de SCFA y la barrera intestinal. Las respuestas individuales varían; las pruebas del microbioma pueden ayudar a personalizar las elecciones.
    ¿Qué alimentos son ricos en fibra fermentable para apoyar la producción de SCFA?
    Legumbres, granos enteros, verduras, frutas y otros alimentos ricos en prebióticos (cebolla, ajo, acedera, etc.).
    ¿Debería tomar probióticos o prebióticos para PCOS e IR?
    Algunas personas pueden beneficiarse, pero las respuestas dependen de la cepa y la dieta. Consulte a un profesional de la salud y elija cepas respaldadas por evidencia.
    ¿Qué es la endotoxinemia metabólica y por qué es relevante?
    Señales inflamatorias elevadas asociadas a una barrera intestinal menos robusta, que pueden afectar la señalización de la insulina.
    ¿Cómo afectan los ácidos biliares y receptores como FXR/TGR5 al control de la glucosa?
    Los microbios transforman los ácidos biliares en metabolitos que activan FXR y TGR5, influyendo en la glucosa, el equilibrio energético y la inflamación.
    ¿Qué es la prueba de InnerBuddies y cómo puede ayudar?
    Muestra cómo funciona tu microbioma (no solo qué comes) para guiar una nutrición personalizada y seguir cambios.
    ¿Qué podría mostrar una prueba del microbioma para guiar cambios dietéticos?
    Podría indicar menor capacidad de producir SCFA, menor diversidad o señales de metabolismo de ácidos biliares alterado.
    ¿Cuánto tiempo suele tardar en verse cambios tras cambios dietéticos o intervenciones del microbioma?
    A menudo semanas o meses; la constancia es clave.
    ¿Los cambios del microbioma pueden sustituir los tratamientos estándar del PCOS?
    No; pueden complementar la atención, pero no sustituyen los tratamientos médicos. Debe discutirse con un médico.
    ¿Hay riesgos o desventajas en las pruebas del microbioma?
    Riesgos directos muy bajos; consideraciones de privacidad y costos; la interpretación requiere un profesional.
    ¿Cómo plantear estrategias basadas en el microbioma a mi médico?
    Explica tus objetivos, pregunta por opciones de prueba y habla de cómo los resultados podrían influir en la dieta y los suplementos.
    ¿Qué señales indican que la salud intestinal está influyendo en los síntomas del PCOS?
    Fluctuaciones de la glucosa, antojos, ganancia de peso, menstruaciones irregulares, acné o exceso de vello pueden ser indicios; consulta a un profesional.

    Hear from our satisfied customers!

    • "I would like to let you know how excited I am. We had been on the diet for about two months (my husband eats with us). We felt better with it, but how much better was really only noticed during the Christmas vacations when we had received a large Christmas package and didn't stick to the diet for a while. Well that did give motivation again, because what a difference in gastrointestinal symptoms but also energy in both of us!"

      - Manon, age 29 -

    • "Super help!!! I was already well on my way, but now I know for sure what I should and should not eat, drink. I have been struggling with stomach and intestines for so long, hope I can get rid of it now."

      - Petra, age 68 -

    • "I have read your comprehensive report and advice. Many thanks for that and very informative. Presented in this way, I can certainly move forward with it. Therefore no new questions for now. I will gladly take your suggestions to heart. And good luck with your important work."

      - Dirk, age 73 -